Emerging CAR-T Strategies in MG

In ‘Emerging CAR-T Strategies in MG,’ our panel explores the potential of cellular therapies targeting CD19, BCMA, or combinations of B-cell and plasma-cell targets. Expert faculty describe early experience with conventional CAR-T approaches in highly treatment-resistant MG and discuss the possibility that profound cellular targeting could produce prolonged disease control following a limited treatment course.

The panel emphasizes, however, that the durability of these responses remains uncertain and will require longer-term follow-up. Conventional CAR-T therapy also introduces substantial practical considerations, including hospitalization, preconditioning, and the need for close monitoring after treatment because of potentially serious complications.

The discussion then turns to mRNA-based CAR-T approaches. Panelists describe emerging trial experience suggesting that these therapies may provide clinical improvement while potentially reducing some of the logistical burden associated with conventional cellular therapy. The faculty note that mRNA-based approaches may be administered in the outpatient setting and have shown a manageable adverse-event profile in early studies, although cytokine release syndrome remains an important consideration.

A key mechanistic difference is persistence. Unlike conventional CAR-T cells, mRNA-based approaches do not remain indefinitely, which may improve controllability but also means that patients may require retreatment. The panel therefore frames CAR-T as a promising but evolving strategy whose future role will depend on balancing efficacy, durability, safety, feasibility, and the need for repeat administration.

Our next episode, ‘Targeting BAFF and APRIL in MG,’ examines an alternative approach to B-cell modulation by interfering with survival signals that support B cells and plasma cells.